CSIMarket Company Name, Ticker, Customers, else..
 
Cue Biopharma Inc   (CUE)
Other Ticker:  
 
 
Price: $2.2300 $-0.07 -3.043%
Day's High: $2.4 Week Perf: -6.69 %
Day's Low: $ 2.15 30 Day Perf: 16.15 %
Volume (M): 234 52 Wk High: $ 5.12
Volume (M$): $ 522 52 Wk Avg: $3.19
Open: $2.33 52 Wk Low: $1.70



 Market Capitalization (Millions $) 103
 Shares Outstanding (Millions) 46
 Employees 50
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) 25
 Capital Exp. (TTM) (Millions $) 0

Cue Biopharma Inc
Cue Biopharma Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. The company is known for its innovative platform technology, called CUE (Control of Unity for Engineered T-Cells), which is designed to harness the body's immune system to fight cancer and other diseases. Cue Biopharma is focused on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells.

The company's primary technology is based on an engineered immune system called Immuno-STATs. Immuno-STATs are a type of molecule that is designed to selectively target and engage immune cells to attack specific disease-causing cells or tissues. This approach has the potential to overcome some of the limitations of traditional immune-based therapies, such as autoimmune reactions in healthy tissue, low response rates, or reduced efficacy over time.

Cue Biopharma's lead product candidate, CUE-101, is a therapeutic, single-chain T cell receptor (sTCR) targeting HPV+ cancers that is being developed for the treatment of head and neck cancer. The company has also developed several other Immuno-STATs, including CUE-102, CUE-103, and CUE-104, which are designed to target other types of cancers, such as melanoma and prostate cancer.

Cue Biopharma's Immuno-STAT platform technology has been validated in several preclinical studies and trials in animals, and the company has received funding and support from several government agencies, including the NIH, the NCI, and the DOD. The company has also entered into collaborations with several leading academic and clinical institutions, including the University of Texas MD Anderson Cancer Center, the Broad Institute of MIT and Harvard, and the Macromoltek Institute.

Cue Biopharma has a highly experienced management team, including President and CEO Daniel Passeri and Chief Medical Officer Ken Pienta, both of whom bring extensive experience in the biopharmaceutical industry. The company is committed to maintaining high ethical standards in all of its operations and has implemented a comprehensive compliance program to ensure that its research and development activities are conducted in accordance with industry best practices and regulatory requirements.

In conclusion, Cue Biopharma is a highly innovative biopharmaceutical company with a strong focus on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells. The company's Immuno-STAT platform technology has the potential to transform the treatment of cancer and other diseases, and its experienced management team and commitment to ethical practices make it a leading player in the biopharmaceutical industry.


   Company Address: 40 Guest Street Boston 2135 MA
   Company Phone Number: 949-2680   Stock Exchange / Ticker: NASDAQ CUE
   CUE is expected to report next financial results on March 20, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.
Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.
Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season



As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.
Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery



As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.





 

Cue Biopharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com